<DOC>
	<DOCNO>NCT01215136</DOCNO>
	<brief_summary>The purpose trial explore activity safety everolimus +/- paclitaxel first-line therapy cisplatin-ineligible patient advance urothelial carcinoma .</brief_summary>
	<brief_title>First-line Everolimus +/- Paclitaxel Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma</brief_title>
	<detailed_description>OUTLINE : This multi-center study Patients enrol one two parallel cohort : - Cohort 1 : impaired renal function AND poor performance status ( cycle length = 28 day ) . Everolimus 10 mg orally daily - Cohort 2 : impaired renal function OR poor performance status ( cycle length = 28 day ) . Everolimus 10 mg orally daily + IV Paclitaxel 80 mg/m2 D1 , 8 , 15 Restaging evaluation perform every 2 cycle . Treatment continue disease progression unacceptable toxicity . Karnofsky performance status 60-70 % Life Expectancy : Not specify Hematopoietic : - Absolute neutrophil count ( ANC ) ≥ 1.5 K/mm3 - Hemoglobin ( Hgb ) ≥ 9 g/dL - Platelets ≥ 100 K/mm3 - INR ≤ 1.5 ( Anticoagulants allow target INR ≤ 1.5 stable dose warfarin stable dose Low molecular weight ( LMW ) heparin least 2 week prior registration protocol therapy ) . - Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L - Fasting triglyceride ≤ 2.5 x ULN . - Fasting serum glucose &lt; 1.5 x ULN Hepatic : - Bilirubin ≤ 1.5 x ULN - Aminotransferases ( AST ALT ) ≤ 2.5 x ULN ( unless liver metastasis , ≤ 5 x ULN ) Renal : - Calculated creatinine clearance &lt; 60 use Cockcroft-Gault formula Cardiovascular : - No symptomatic congestive heart failure New York heart Association Class III IV . - No unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction within 6 month start study drug , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histological cytological proof transitional cell carcinoma ( TCC ) bladder , urethra , ureter , renal pelvis ( urothelial carcinoma ) . Histology may mix , still require component TCC . Measurable disease accord RECIST obtain image within 30 day prior registration protocol therapy . Must ineligible cisplatin , base following , within 30 day prior registration protocol therapy . Prior radiation therapy allow &lt; 25 % bone marrow . Written inform consent HIPAA authorization release personal health information . Age &gt; 18 year time consent . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) time consent sign 8 week treatment discontinuation . Females childbearing potential must negative pregnancy test within 7 day prior prior registration protocol therapy . Females must breastfeed . No prior chemotherapy metastatic disease . Prior chemotherapy neoadjuvant/adjuvant setting allow complete least 12 month prior registration protocol therapy . No active CNS metastasis leptomeningeal metastasis . Patients neurological symptom must undergo head CT scan brain MRI exclude brain metastasis . No prior malignancy allow except adequately treat basal cell adequately treat squamous cell skin cancer , situ cervical cancer , Gleason ≤ grade 7 prostate cancer ( treat definitively evidence PSA progression ) , cancer patient diseasefree least 5 year . No treatment anticancer therapy investigational agent within 30 day prior registration protocol therapy . No known hypersensitivity protocol treatment . No prior treatment mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) . No history immunization attenuate live vaccine within one week prior registration protocol therapy study period . No severely impaired lung function define spirometry DLCO 50 % normal predict value and/or 02 saturation 88 % less rest room air . No uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN . No active ( acute chronic ) uncontrolled severe infection . No liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis . No known history HIV seropositivity . No impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . No active , bleeding diathesis . No history major surgery ( define require general anesthesia ) significant traumatic injury within 30 day prior registration protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>